Pharmaceutical company Indivior PLC said Friday that is has filed opioid addiction treatment drug Sublocade for regulatory approval with Australia’s Therapeutic Goods Administration.
Sublocade injection, which is intended to treat moderate to severe opioid use disorder, has already been approved by the US Food and Drug Administration and Health Canada’s New Drug Submission. The drug delivers buprenorphine through a slow-release gel that is injected under the skin.
If approved, the drug will be marketed in Australia by Indivior Pty Ltd. The company noted that “illicit opioid use” contributed to more than a thousand deaths in Australia in 2016.
Shares in Indivior were down 0.2% at 471.50 pence on Friday afternoon.